Table 5.
Clinical outcomes of the 71 patients described in case reports or case series.
| Patient demographics | |
| Mean age (years) | 27.2 (range 1.3–58) |
| Sex (% male) | 40.8% |
| Poisoning exposure | |
| Mean carbamazepine ingestion (grams) | 20.9 (0.7–120) |
| Mean peak carbamazepine concentration (mg/L) | 46.2 (range 20–130) |
| Mean delay between ingestion and admission (hours) | 7.8 (range 1–28) |
| Clinical symptoms and signs | |
| Respiratory depression | 39.4% |
| Decreased consciousness | 100% |
| Seizure (1 or more) | 40.8% |
| Hypotension | 18.3% |
| Dysrhythmias | 12.7% |
| Other administered | |
| MDAC | 33.8% |
| Mechanical ventilation | 56.3% |
| ECTR | |
| Hemodialysis | 16.9% |
| Hemoperfusion | 42.2% |
| Continuous renal replacement therapy | 5.6% |
| Hemoperfusion-Hemodialysis | 5.6% |
| Therapeutic plasma exchange | 7.0% |
| Others | 5.6% |
| More than 1 ECTR | 16.9% |
| Outcome | |
| Sequelae | 1.4% |
| Fatalities | 4.2% |
MDAC, Multiple-dose activated charcoal; ECTR, Extracorporeal treatment.
*The other fatalities were described in observational cohorts`.